First analysis from ASCEND-2 confirms high detection rates and specificity achieved with multi-biomarker approach in most aggressive cancers and those with no standard-of-care screening test1
.
Exact Sciences (EXAS) to Present Late-Breaking Data from ASCEND-2 Study Validating Its Investigational Multi-Cancer Early Detection Test at AACR streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Exact Sciences Advances Early Cancer Detection and Precision Oncology Programs with Data Presentations at ESMO 2023 Annual Congress streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
MADISON, Wis., Oct. 20, 2023 /PRNewswire/ Exact Sciences Corp. , a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company s.